Cargando…

Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations

The natriuretic peptides, especially the B-type peptide (BNP) and its inactive split-product N-terminal proBNP (Nt-proBNP) are increasingly used in screening for heart failure, primarily with reduced systolic function, in patients with symptoms suggestive of heart failure, as well in the stable (Gen...

Descripción completa

Detalles Bibliográficos
Autor principal: Hildebrandt, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833235/
https://www.ncbi.nlm.nih.gov/pubmed/19773612
http://dx.doi.org/10.3233/DMA-2009-0632
_version_ 1782291813123489792
author Hildebrandt, Per
author_facet Hildebrandt, Per
author_sort Hildebrandt, Per
collection PubMed
description The natriuretic peptides, especially the B-type peptide (BNP) and its inactive split-product N-terminal proBNP (Nt-proBNP) are increasingly used in screening for heart failure, primarily with reduced systolic function, in patients with symptoms suggestive of heart failure, as well in the stable (General Practitioner) setting as in the acute setting. Supporting this use is a very strong prognostic value of the natriuretic peptides. This has been shown in as well heart failure as acute coronary syndromes, but also in the general population and in high-risk groups as patients with diabetes, hypertension and coronary artery disease. This has of course raised interest for the use of the natriuretic peptides as a risk marker and for screening for heart failure with reduced systolic function in these populations. In symptomatic persons and in high risk populations, the natriuretic peptides have demonstrated a high sensitivity for ruling out the disease, if the right decision limits are choosen. Thus the number of normal echocardiographies can be reduced. More recently, the use in screening asymptomatic persons for left ventricular systolic dysfunction has gained more interest. In the unselected population, screening would probably not be cost-effective. In populations with a higher pre-test probability for heart failure, as patients with diabetes, hypertension and stable coronary artery disease, screening would presumably be more cost-effective, but evidence for the use in this setting is still lacking.
format Online
Article
Text
id pubmed-3833235
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-38332352013-12-10 Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations Hildebrandt, Per Dis Markers Other The natriuretic peptides, especially the B-type peptide (BNP) and its inactive split-product N-terminal proBNP (Nt-proBNP) are increasingly used in screening for heart failure, primarily with reduced systolic function, in patients with symptoms suggestive of heart failure, as well in the stable (General Practitioner) setting as in the acute setting. Supporting this use is a very strong prognostic value of the natriuretic peptides. This has been shown in as well heart failure as acute coronary syndromes, but also in the general population and in high-risk groups as patients with diabetes, hypertension and coronary artery disease. This has of course raised interest for the use of the natriuretic peptides as a risk marker and for screening for heart failure with reduced systolic function in these populations. In symptomatic persons and in high risk populations, the natriuretic peptides have demonstrated a high sensitivity for ruling out the disease, if the right decision limits are choosen. Thus the number of normal echocardiographies can be reduced. More recently, the use in screening asymptomatic persons for left ventricular systolic dysfunction has gained more interest. In the unselected population, screening would probably not be cost-effective. In populations with a higher pre-test probability for heart failure, as patients with diabetes, hypertension and stable coronary artery disease, screening would presumably be more cost-effective, but evidence for the use in this setting is still lacking. IOS Press 2009 2009-09-21 /pmc/articles/PMC3833235/ /pubmed/19773612 http://dx.doi.org/10.3233/DMA-2009-0632 Text en Copyright © 2009 Hindawi Publishing Corporation.
spellingShingle Other
Hildebrandt, Per
Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations
title Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations
title_full Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations
title_fullStr Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations
title_full_unstemmed Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations
title_short Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations
title_sort natriuretic peptides: prediction of cardiovascular disease in the general population and high risk populations
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833235/
https://www.ncbi.nlm.nih.gov/pubmed/19773612
http://dx.doi.org/10.3233/DMA-2009-0632
work_keys_str_mv AT hildebrandtper natriureticpeptidespredictionofcardiovasculardiseaseinthegeneralpopulationandhighriskpopulations